Oral Magnesium Supplementation in Adults With Coronary Heart Disease or Coronary Heart Disease Risk

J Am Acad Nurse Pract. 2009 Dec;21(12):651-7. doi: 10.1111/j.1745-7599.2009.00460.x.

Abstract

Purpose: To review randomized control clinical trial (RCT) literature and prospective studies for the safety and efficacy of magnesium supplements in patients with coronary heart disease (CHD) or with CHD risk.

Data sources: Databases were searched using the keywords: magnesium, heart disease, endothelium, prevention, treatment, therapy, level, and supplement.

Conclusions: There were no reports of adverse effects from magnesium supplementation in any of the studies. Subjects reporting lower dietary magnesium intake had significantly lower serum magnesium concentrations than those reporting higher dietary magnesium intake and, in some cases, had a significantly higher frequency of supraventricular beats. There was a modest relationship between dietary magnesium intake and a reduced risk of CHD in male subjects; however, there was no noted decrease in the development of CHD disease in women who had high magnesium intake.

Implications for practice: Magnesium is vital for many functions in the body and magnesium supplementation is safe. There is a possible association between a modestly lower risk of CHD in men and increased magnesium intake; therefore, it is reasonable to encourage diets high in magnesium as a potential means to lower the risk of CHD.

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Adult
  • Coronary Disease / epidemiology
  • Coronary Disease / etiology
  • Coronary Disease / prevention & control*
  • Diet
  • Dietary Supplements*
  • Female
  • Humans
  • Magnesium / administration & dosage*
  • Magnesium / metabolism
  • Magnesium / physiology
  • Magnesium Deficiency / complications
  • Magnesium Deficiency / epidemiology
  • Magnesium Deficiency / prevention & control*
  • Male
  • Nutrition Policy
  • Nutritional Requirements
  • Prospective Studies
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Risk Reduction Behavior
  • Safety
  • United States / epidemiology

Substances

  • Magnesium